Elucidating Tau function and dysfunction in the era of cryo-EM

Guy Lippens*1 and Benoit Gigant*

From the Institut d’Ingénierie des Systèmes Biologiques (LISBP), Université de Toulouse, CNRS, INRA, INSA, 135 avenue de Rangueil, 31077 Toulouse Cedex 04, France and the Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Université Paris-Sud, Université Paris-Saclay, 91198 Gif-sur-Yvette Cedex, France

Edited by Paul E. Fraser

Tau is a microtubule-associated protein involved in the regulation of axonal microtubules in neurons. In pathological conditions, it forms fibrils that are molecular hallmarks of neurodegenerative disorders known as tauopathies. In the last 2 years, cryo-EM has given unprecedented high-resolution views of Tau in both physiological and pathological conditions. We review here these findings and put them into the context of the knowledge about Tau before this structural breakthrough. The first structures of Tau fibrils, a molecular hallmark of Alzheimer’s disease (AD), were based on fibrils from the brain of an individual with AD and, along with similar patient-derived structures, have set the gold standard for the field. Cryo-EM structures of Tau fibers in three distinct diseases, AD, Pick’s disease, and chronic traumatic encephalopathy, represent the end points of Tau’s molecular trajectory. We propose that the recent Tau structures may call for a re-examination of databases that link different Tau variants to various forms of dementia. Because this structural information on Tau was obtained in a very short period (the last 2 years), we propose here to analyze the recent cryo-EM structure of Tau on MTs (19) has complemented our functional view of this archetypal intrinsically disordered protein (20). Because all of this information on Tau was obtained in a very short period (the last 2 years), we propose here to analyze the novel structures in view of past structural and functional data and thereby to also define some remaining questions about its (dys)function. Starting from a comparative analysis of the global form of Tau fibers, we will zoom in on a particular peptide that has long been considered a nucleus of the aggregation process. We will illustrate how the novel structures also point to the need for a re-examination of the mutational databases that link Tau mutants to different forms of dementia. Finally, we address the question of whether and how functional and pathological aspects of Tau might be linked through the recent structural information.
Structure–(dys)function relationships of Tau before the cryo-EM data

Tau was discovered as a protein involved in the assembly of tubulin into microtubules and their consequent stabilization (18). Other functions have been described (21), but as the structural information in these contexts is lacking, we will not treat them in the present review. Tau is notably characterized by the presence of three or four (according to the isoforms) imperfect repetitions of a motif of about 30 residues, known as the microtubule-binding repeats (MTBRs) (Fig. 1). Strictly speaking, each repetition is composed of an 18-amino acid imperfect repeat and a 13–14-residue interrepeat region (22), and we will make the distinction when necessary.

N-terminal to the MTBR region is a proline-rich region (PRR), and these two regions are flanked by N-terminal and C-terminal extensions (Fig. 1). Early efforts to establish a structure–function relationship were based on affinity measurements of different Tau fragments to taxol-stabilized MTs. This study found (i) Tau protein binding primarily to the exterior surfaces of MTs; (ii) a negative contribution of the Tau N-terminal extension; (iii) an unstructured, noncooperative, and distributed binding by the different repeats, with the first repeat R1 binding /H11011 100 times more tightly than the other repeats; and (iv) within the repeats, no significant effect of the less conserved interrepeat regions (20). The last conclusion was, however, based on truncations of only the R3 interrepeat, whereas later studies showed that the R1 interrepeat does contribute to the MT binding (23). An additional fragment in the PRR (Fig. 1) was equally found to contribute significantly to the affinity (24, 25) and led to a “jaws” model, whereby this flanking PRR (and the sequence downstream of the fourth repeat) would position the repeat peptides to promote tubulin assembly (26). However, no atomic-level structural information about Tau on the MT surface was available to provide mechanistic insights into the functional aspects of Tau. One notable caveat is that most studies were done with taxol-stabilized MTs; it is not clear yet whether the same results will hold when Tau is allowed to copolymerize with tubulin as is the case in the neuron (27). From the NMR study of a functional fragment of Tau (TauF4, corresponding to the Ser^{208}–Ser^{325} fragment of Tau; numbering throughout this paper is according to the longest isoform) (25) bound to a nonpolymerizable complex of two tubulin heterodimers sequestered by a stathmin-like domain protein, we proposed a model whereby the 258SKIGSTE264 peptide, embedded in the first repeat that by itself can already stimulate MT assembly (28), would bridge different tubulin dimers and change conformation in the assembly process (29). We will provide below a detailed discussion of this model in view of the recent cryo-EM data of Tau on the MT surface.

The above-described line of research converged with that started by Alois Alzheimer when it was realized by different groups that the neuronal tangles, one of the molecular hallmarks of AD, are composed primarily of aggregates of the same Tau protein that promotes MT assembly (30–33). Further important evidence for Tau having a direct role in neurodegeneration came from the identification of distinct mutations leading to neuronal degeneration and dementia (34–36) that are, however, distinguishable from AD.

Knowledge at the structural level of Tau fibrils before the cryo-EM boom was scarce at best. Most studies have relied on synthetic fibers, commonly induced by incubating recombinant Tau forms with negatively charged polyanions, with heparin being the most popular (15, 16). Although solid-state NMR and EPR were able to assign β-strands to certain peptides (37–40) in such synthetic fibers, no atomic model was available. The crystal structure of the PHF6 peptide, thought to be a nucleus of the aggregation process (41), came out 12 years ago and described a zipper-like structure with a dry interface (42). As we will discuss below, the recent cryo-EM data on brain-derived natural fibers entirely challenges both the model of heparin-induced synthetic fibers and the biological relevance of structural data derived from the peptide crystals.

Although ill-defined, “hyperphosphorylation” is a characteristic term that is used to describe Tau in the fibrillar aggregates.
that characterize AD and other related dementia (commonly called “tauopathies”) (43). Accordingly, the present method of choice to clinically stage AD is by post-mortem staining of the neurons of deceased patients with the AT8 antibody (44), whose epitope was identified as the Tau peptide centered on the phosphorylated residues Ser202 and Thr205 in the PRR. Although NMR (45) and X-ray crystallography (46) gave some insights into the structural aspects of this epitope, with notably a question of whether a third phosphorylation event at Ser208 should be included in the epitope, how this epitope and, for that matter, the whole PRR connects to the fibril core is not clear at this moment. The divergence between the physiological (MT assembly) and pathological (aggregation into fibers) aspects of Tau, imposed by the loose statement “Tau gets hyperphosphorylated, detaches from the MT and becomes prone to aggregation” (47), obviously needs clarification in terms of the location and stoichiometry of the phosphorylation pattern.

In summary, the available structural data described Tau as an archetypal intrinsically disordered protein that binds to MTs in a dynamic manner and transforms into a β-sheet–rich rigid core region upon aggregation and whose function and dysfunction are regulated by numerous post-translational modifications, among which phosphorylation stands out. Detailed understanding of these different aspects was lacking because of the absence of atomic-level structures and has only become available in the last couple of years.

The global fold of Tau fibers differs substantially between ex vivo and synthetic samples

Paired helical filaments in the neurons of Alzheimer’s disease patients were first described (48) and subsequently shown (49) by EM in the early 1960s. It then took some 22 years before image reconstruction by EM led to the first model of the cross-section of these fibrils (50). Finally, some 32 years elapsed before cryo-EM turned this image into an atomic-level structure of the fibrils (12) (Fig. 2). The two latter studies equally confirmed that straight filaments, a minor fraction of the Tau fibrils in AD brains, are composed of the same protofilament structure, but with a different packing. Whether the straight filaments that are dominant in progressive supranuclear palsy (51) adopt the same fold remains to be seen. In view of the extensive polymorphisms that amyloid structures can adopt (52), the currently published filament structures may represent only a small fraction of the Tau filament landscape, as there are numerous other tauopathies where atomic structures are still lacking. Nevertheless, these novel structures were eagerly awaited, as for the first time, it could be said with a high degree of confidence that they are the “real thing.” The identical structures of the fibers derived from different patients (53) furthermore underscore the idea that we are considering a disease-rather than patient-specific amyloid form of the Tau fibers.

When considering the molecular arrangement of Tau in the AD fibrils, the most unexpected feature is the β-helical fold formed by the triangular arrangement of three consecutive β-sheets (12). This structure is also observed in the recent cryo-EM structure of fibrils from brains of CTE patients (professional sportsmen suffering from a specific tauopathy due to repeated head impact), but in this case, it lines a wider cavity with a presently unknown (hydrophobic) molecule (14). Composed of residues in the fourth MTBR (Fig. 1), this β-helix is rather reminiscent of a folded protein. The peculiar character

Figure 2. Structural detail as available over time for the Tau fibers formed in the brain of AD patients. Left, negative-stain EM image of brain tissue showed the first PHFs (49). Middle, reconstructed cross-section of the paired helical filament (50). Right, atomic model of the same cross-section obtained by cryo-EM (12).
of the turn is highlighted when we consider the Ramachandran plot of the structure, with Asp$^{348}$ and Arg$^{349}$ the only two residues characterized by positive $\Phi, \Psi$ angles (Fig. 3). When we query the Protein Data Bank (PDB) with the sequence (DFKDRV) of the peptide centered around these two residues, a unique structure of a single-chain fragment variable antibody (PDB code 6EHV), this fragment adopts a turn comparable with the one found in the AD-Tau fibrils (Fig. 3), underscoring its character of “folded protein.” Finally, this same (DFKDRV) peptide was found to enhance the affinity for the MT surface of a Tau fragment spanning the first three repeats by a factor of 2.5 (20), so it remains an open question what conformation this peptide adopts in the physiological conformation of Tau and notably at the microtubule surface (see below).

In contrast to this peculiar conformation in the AD-Tau fibers, the same Phe$^{346}$–Val$^{350}$ peptide observed in the fibers isolated from the brain of a PiD patient, mainly composed of the shorter 3R isoforms, adopts a rather common extended conformation (13). Subtle forces can hence push the structure toward completely different packings. The relationship with the aggregation process and the possible intervention of cofactors and/or post-translational modifications of Tau is at this moment unresolved.

To compare the ex vivo fibers with the synthetic heparin-induced fibers, the same team used cryo-EM to solve the atomic-level structure of the latter. Despite the resemblance of the macroscopic structures as seen under negative-stain EM, differences at the atomic level are massive. The ordered core of the heparin-induced fibrils as seen by cryo-EM extends from Gly$^{272}$ to His$^{330}$ and thereby hardly overlaps with the core of AD paired helical filaments (PHFs) spanning the fragment from Val$^{306}$ to Phe$^{378}$. The structures do, however, explain why heparin readily induces fibrils with our TauF4 fragment, which overlaps perfectly with the former observed core region (55). The turn region observed in AD PHFs is evidently not visible in the heparin-induced fibrils, but at least in the synthetic fibers obtained with 4R-Tau, the chain does turn on itself around a peptide centered in the R2 repeat (Lys$^{290}$–Pro$^{301}$) (17). In the synthetic fibers obtained with 3R-Tau, where this R2 repeat is missing, no turn is observed, but rather two molecules of Tau stacking in a parallel manner are identified. One might speculate that different cofactors or altered reaction conditions from the ones that were chosen for the in vitro experiments could produce additional types of filaments.

In conclusion, the combined cryo-EM structures clearly indicate that at the atomic level, brain-derived fibers are disease-specific and are substantially different from the heparin-derived synthetic fibers that have been used in previous studies.

The PHF6 peptide adopts different conformations among the available fiber structures

The PHF6 peptide motif, spanning the 6 residues $^{306}$VQI$^{311}$ in the third repeat of Tau (Fig. 1), was early on identified as one of the hot spots of the aggregation behavior (41). This same peptide motif is at the very beginning of the ordered structure of the brain-isolated AD fibrils (12). Earlier X-ray microcrystallography on crystals of the isolated peptide showed a homotypic interaction, whereby one PHF6 peptide locks into a second antiparallel one to form a sterically rigid with a dry interface (42) (Fig. 4). In the AD fibrils, however, the same PHF6 motif locks into the $^{377}$HKLTF$^{378}$ sequence, with Leu$^{376}$ intercalating between the Ile$^{308}$ and Tyr$^{310}$ side chains (12) (Fig. 4). At the center of the pseudorepeat region Lys$^{369}$–Thr$^{380}$ directly following the MTBRs, this peptide motif also contributes largely to the MT binding of 3R- or 4R-Tau in neuronal processes through decreasing the dissociation rate (56). Ironically, whereas the first synthetic fibers without heparin were obtained with the K11 or K12 fragments running to Tyr$^{394}$ in the 3R- or 4R-Tau constructs and hence spanning this Lys$^{369}$–Thr$^{380}$ sequence (57), the shorter K18 or K19 fragments, later extensively used as a proxy to study the aggregation of full-length Tau (58, 59), stop at Lys$^{372}$ (Fig. 1) and hence are strictly unable to provide the complement of the PHF6 sequence found in AD PHFs.
In the PiD 3R-Tau fiber structure, the same PHF6 fragment could potentially face the same 374HKLTF378 sequence. But intriguingly, it faces another peptide from Tau, with this time the two hydrophobic side chains of Val337 and Val339 intercalating between the Val306-Ile308-Tyr310 side chains (Fig. 4)(13). And even more surprisingly, in the cryo-EM structure of heparin-induced synthetic fibers with 4R-Tau as starting material, this PHF6 sequence is literally turned inside-out, with its Val306-Ile308-Tyr310 side chains facing the outside of the fibril (Fig. 4). The side chain of Lys311 equally points outside, probably through interaction with the negatively charged heparin. Indeed, introducing a negative charge at this position was previously found to reduce aggregation in the heparin-induced aggregation assay (60). Only in the heparin-induced 3R-Tau fibrils, where two Tau molecules stack to make a fibrillary structure (rather than one single Tau molecule bending over itself to form a protofilament), do the PHF6 peptide sequences on the molecules face one another (17). However, they do so in a parallel manner, which further underscores the extreme polymorphism of which Tau is capable. One should remember that the initial study identifying this hot spot of aggregation used both a 3R-Tau construct (the K19 fragment) and heparin as inducer (41), and the latter structure is hence most relevant to interpret the results. As the peptide does adopt a β-strand conformation in all structures, the conclusion of the mutational analysis that a proline in whatever position of PHF6 abolishes fiber formation (41, 61) might, however, well hold up for every type of fibril.

The crystal structure of the PHF6 peptide, describing the steric zipper with a dry interface (42), has spurred a large research effort both to interpret at the structural level aggregation inhibitors described in the past (62–64) or to rationally develop novel inhibitors(62, 65, 66). Many of these were tested first in an in vitro assay monitoring the polyanion-induced aggregation of some Tau construct before being tested in a cell model or a transgenic organism. An important issue is that we do not know the atomic structure of Tau fibrils in the latter models, but at least in those based on overexpression of the K18/K19 fragments, the lack of the C-terminal 374HKLTF378 peptide implies that these Tau fragments cannot adopt the AD brain-derived conformation. A shift toward the dGAE frag-
ment (67), which comprises residues from Asp$^{297}$ to Glu$^{391}$ (Fig. 1) and spans the sequence of Tau that is ordered in the AD PHFs, could possibly reproduce the spatial organization of the ex vivo fibrils, although this has still to be proven. Whether it is opportune to add to this fragment 16 N-terminal residues visible as an unsharpened density in the AD fiber structure (12) remains an open question.

In conclusion, the presently available structures of brain-derived fibrils and their substantial differences from the heparin-induced synthetic fibrils, in particular the differential positioning of the PHF6 peptide in these structures, invite a re-evaluation of the inhibitors in this new framework.

Revisiting Tau mutations leading to non-AD dementia in view of the novel structures

Although absent in Alzheimer’s disease, these mutations can either affect the ratio of 3R/4R-Tau splicing variants, with PiD (31, 68) for example being mostly characterized by a dominant expression of 3R forms (69), or can directly introduce a point mutation without notably affecting the splicing ratio. Generally, these mutations have been first identified in a family with a history of precocious dementia, and the recombinant proteins are then evaluated in terms of their aggregation behavior and/or their capacity to assemble tubulin into microtubules. However, the aggregation assay in most cases concerns the heparin-induced fiber formation, monitored by some fluorescence method (70) and/or negative-stain EM imaging of the resulting fibers. In view of the pronounced structural differences between the ex vivo fibrils and the heparin-induced ones, we probably should reconsider these findings. One caveat hereby is that these mutations could cause still entirely different structures compared with the three available disease models. As the history of precocious dementia, and the recombinant proteins are then evaluated in terms of their aggregation behavior and/or their capacity to assemble tubulin into microtubules. However, the aggregation assay in most cases concerns the heparin-induced fiber formation, monitored by some fluorescence method (70) and/or negative-stain EM imaging of the resulting fibers. In view of the pronounced structural differences between the ex vivo fibrils and the heparin-induced ones, we probably should reconsider these findings. One caveat hereby is that these mutations could cause still entirely different structures compared with the three available disease models. As the history of precocious dementia, and the recombinant proteins are then evaluated in terms of their aggregation behavior and/or their capacity to assemble tubulin into microtubules. However, the aggregation assay in most cases concerns the heparin-induced fiber formation, monitored by some fluorescence method (70) and/or negative-stain EM imaging of the resulting fibers. In view of the pronounced structural differences between the ex vivo fibrils and the heparin-induced ones, we probably should reconsider these findings. One caveat hereby is that these mutations could cause still entirely different structures compared with the three available disease models. As the history of precocious dementia, and the recombinant proteins are then evaluated in terms of their aggregation behavior and/or their capacity to assemble tubulin into microtubules. However, the aggregation assay in most cases concerns the heparin-induced fiber formation, monitored by some fluorescence method (70) and/or negative-stain EM imaging of the resulting fibers. In view of the pronounced structural differences between the ex vivo fibrils and the heparin-induced ones, we probably should reconsider these findings. One caveat hereby is that these mutations could cause still entirely different structures compared with the three available disease models. As the history of precocious dementia, and the recombinant proteins are then evaluated in terms of their aggregation behavior and/or their capacity to assemble tubulin into microtubules. However, the aggregation assay in most cases concerns the heparin-induced fiber formation, monitored by some fluorescence method (70) and/or negative-stain EM imaging of the resulting fibers. In view of the pronounced structural differences between the ex vivo fibrils and the heparin-induced ones, we probably should reconsider these findings. One caveat hereby is that these mutations could cause still entirely different structures compared with the three available disease models. As the history of precocious dementia, and the recombinant proteins are then evaluated in terms of their aggregation behavior and/or their capacity to assemble tubulin into microtubules. However, the aggregation assay in most cases concerns the heparin-induced fiber formation, monitored by some fluorescence method (70) and/or negative-stain EM imaging of the resulting fibers. In view of the pronounced structural differences between the ex vivo fibrils and the heparin-induced ones, we probably should reconsider these findings. One caveat hereby is that these mutations could cause still entirely different structures compared with the three available disease models. As the history of precocious dementia, and the recombinant proteins are then evaluated in terms of their aggregation behavior and/or their capacity to assemble tubulin into microtubules. However, the aggregation assay in most cases concerns the heparin-induced fiber formation, moni

Tau conformations in function and dysfunction might be related

Whereas the crystal structure of tubulin in its polymerized form was determined by electron crystallography some 20 years ago (77), we had to wait until last year for cryo-EM to yield the first atomic-resolution view of Tau on the MT surface (19). Although these structures should be considered with some caution—they show an artificial construct built from a repetition of a single repeat (R1, as the largest contributor of binding energy (20), or R2, the second repeat that distinguishes 4R- from 3R-Tau), the constructs were added in excess of tubulin, and near-atomic resolution was only obtained with peluroside as a stabilizing agent and even then required extensive modeling—they do contain important novel information that completes past indirect evidence. First, the structure places the $^{258}$SKIGSTEN$^{265}$ peptide in the first repeat at the interface of two tubulin dimers, where an $\alpha_2$ subunit contacts the $\beta_2$ subunit of the next dimer (Fig. 5). NMR analysis of a Tau construct bound to soluble tubulin assemblies not only localized this peptide at exactly the same position, but suggested that it would transit from a turn toward an extended conformation when a second tubulin dimer comes in (29). The cryo-EM structure of the R1 repeat adopts a remnant of such a turn and thereby confirms the proposed mechanism (Fig. 5). As we dispose now of another structure of this R1 repeat, in the cryo-EM structure of the Pick’s disease fibrils, it is interesting to link the functional and dysfunctional conformations of Tau. Indeed, in the 3R-Tau structure of PiD fibrils, the same $^{258}$SKIGSTEN$^{265}$ peptide adopts a perfect turn conformation, stabilized by a salt bridge between the side chains of Lys$^{259}$ and Glu$^{264}$ (Fig. 5). On the
tubulin surface, this bridge could break when a novel tubulin dimer comes in, with Lys\textsuperscript{259} now forming a salt bridge with Asp\textsuperscript{424}, whereas Glu\textsuperscript{264} stabilizes the α\textsubscript{1}/β\textsubscript{2} interaction through a salt bridge with β\textsubscript{2} Lys\textsuperscript{402}. Beyond proving that the turn conformation is possible, the combined structures hence provide an additional link between Tau’s functional and pathological conformations, in line with previous studies that hint at a role for tubulin in the aggregation process. Whether in vivo aggregation of Tau occurs at the microtubule surface\textsuperscript{(78, 79)} or rather through the soluble tubulin\textsuperscript{(80)} remains unclear but could be related to the recent controversy whether Tau stabilizes MTs or enables these same axonal MTs to have labile domains\textsuperscript{(81, 82)}.

The second repeat, spanning residues Lys\textsuperscript{274–Gly}\textsuperscript{304}, was also resolved by cryo-EM and Rosetta modeling. Its conformation is extended and spans three tubulin units\textsuperscript{(19)}. Because this second repeat is invisible in the AD PHF structure and missing in the PiD 3R-Tau fibrils, we can only compare it with the same fragment in the heparin-induced 4R-Tau filaments. Although there too it adopts an extended conformation, overlap of both fragments is poor, with a general root mean square deviation of 4.5 Å. Further structural studies, notably with fragments spanning different repeats, are awaited to explain the effect of mutations and/or post-translational modifications (PTMs).

Conclusions and perspectives

As indicated before, the present cryo-EM structures of Tau fibers in three distinct diseases, AD, PiD, and CTE, represent the end points of the molecular trajectory of pathological Tau. Together with the tubulin-bound structure, however, it means that we now dispose of a structural glimpse of several stages in the lifetime of Tau, from its microtubulin bound to fiber conformation. Importantly, the slow turnover of Tau in the brain, which can span days or even weeks\textsuperscript{(83)}, suggests that individual molecules can take many paths. Proposed trajectories that were derived without those constraints (or with the wrong constraints, if we consider the heparin-induced fibrils), can now be re-evaluated in terms of the end points.

In all structures, large parts of Tau and notably the PRR (Fig. 1) are absent. This latter PRR contributes importantly to microtubule binding\textsuperscript{(25)}. It is equally one of the main regions regulated by PTMs and notably phosphorylation. The resulting heterogeneity (with many “mod-forms”\textsuperscript{(84)} or “proteoforms”\textsuperscript{(85)} if we include the splice variants) will necessarily reduce the constraint of homogeneity that cryo-EM can detect. Nevertheless, clinically, AD is diagnosed and staged post-mortem by the AT8 antibody raised against a phospho-epitope in this PRR\textsuperscript{(44)}. The definition of the latter epitope has equally evolved over the last quarter of a century, and currently, it is not clear whether the antibody “sees” two (Ser\textsuperscript{202} and Thr\textsuperscript{205}) or three (with an additional Ser\textsuperscript{208}) phosphorylated residues on AD-Tau\textsuperscript{(46)}. Importantly, the absence of these regions in the present structures therefore does not necessarily indicate their lack of importance but might rather be a consequence of their heterogeneous nature in the neuron.

A last but most important open question that is not answered (yet) by the structures remains the identification of the driving force(s) for aggregation. Is the specific phosphorylation pattern that can drive aggregation in vitro\textsuperscript{(86)} also at work in vivo? What about the role of other PTMs, such as acetylation of lysines\textsuperscript{(87–89)}, O-GlcNacylation\textsuperscript{(90, 91)}, or others? But it also raises the more general (and pressing) question about the structure of Tau fibers in all models, be they at the level of molecules, cells, or organisms. Even if these models are imperfect, we need to ascertain whether they obey the structural constraint of the end point, with fibers of a comparable structure as the brain-derived ones. Negative-stain EM and thioflavin fluorescence cannot answer this question at a sufficient resolution, but we can hope that the increased access to cryo-EM platforms will provide a structural evaluation of the different models at the atomic level. With comparable filaments at the atomic level, we...
can hope that the trajectory of Tau mimics what is happening in the patient’s brain. As such, the recently derived structures set a standard and should open a new era of increased pathological relevance of models at all length scales.

Acknowledgments—We thank Prof. M. Goedert (Cambridge, UK), who provided in advance the structures of heparin-induced filaments and CTE fibers and whose insightful comments helped to shape this review. We equally thank Dr. C. Byrne (Paris, France) for careful proofreading of the manuscript.

References

1. Cheng, Y. (2018) Single-particle cryo-EM—how did it get here and where will it go. Science 361, 876 – 880 CrossRef Medline
2. Renaud, J.-P., Chari, A., Ciferri, C., Liu, W.-T., Rémygi, H.-W., Stark, H., and Wissmann, E. (2018) Cryo-EM in drug discovery: achievements, limitations and prospects. Nat. Rev. Drug Discov. 17, 471 – 492 CrossRef Medline
3. Bai, X.-C., Yan, C., Yang, G., Hou, S., Sun, L., Zhang, M., and Shi, Y. (2015) An atomic structure of human γ-secretase. Nature 525, 212 – 217 CrossRef Medline
4. Lu, P., Bai, X.-C., Ma, D., Xie, T., Yan, C., Sun, L., Yang, G., Zhao, Y., Zhou, R., Scheres, S. H. W., and Shi, Y. (2014) Three-dimensional structure of human γ-secretase. Nature 512, 166 – 170 CrossRef Medline
5. Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., and Shi, Y. (2019) Recognition of the amyloid precursor protein by human γ-secretase. Science 363, eaaw0930 CrossRef Medline
6. Yang, G., Zhou, R., Zhou, Q., Guo, X., Yan, C., Ke, M., Lei, J., and Shi, Y. (2019) Structural basis of Notch recognition by human γ-secretase. Nature 565, 192 – 197 CrossRef Medline
7. Laverty, D., Desai, R., Uchayama, T., Misumi, T., Bredt, D., and Schröder, G. F. (2017) Fibril structure of amyloid-β(1–42) by cryo-electron microscopy. Science 358, 116 – 119 CrossRef Medline
8. Guerrouer-Ferreira, R., Taylor, N. M., Mon, D., Ringler, P., Lauer, M. E., Riek, R., Britschgi, M., and Stahlberg, H. (2018) Cryo-EM structure of α-synuclein fibrils. eLife 7, e36402 CrossRef Medline
9. Li, B., Ge, P., Murray, K. A., Sheth, P., Zhang, N., Nair, G., Sawaya, M. R., Shin, W. S., Boyer, D. R., Ye, S., Eisenberg, D. S., Zhou, Z. H., and Jiang, L. (2018) Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel. Nat. Commun. 9, 3609 CrossRef Medline
10. Crowther, R. A. (1996) Cryo-EM in drug discovery: achievements, limitations and prospects. Nat. Rev. Drug Discov. 17, 471 – 492 CrossRef Medline
11. Goedert, M. (1996) Microtubule-associated protein tau: a component of Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550 – 553 CrossRef Medline
12. Pérez, M., Valpuesta, J. M., Medina, M., Monteo de García, E., and Avila, J. (1996) Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. J. Neurochem. 67, 1183 – 1190 CrossRef Medline
13. Goode, B. L., and Feinstein, S. C. (1994) Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J. Cell Biol. 124, 769 – 782 CrossRef Medline
14. Goode, B. L., Denis, P. E., Panda, D., Radeke, M. J., Miller, H. P., Wilson, L., and Feinstein, S. C. (1997) Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Mol. Biol. Cell 8, 353 – 365 CrossRef Medline
degeneration and related neurodegenerative disorders linked to chromosome 17. *Proc. Natl. Acad. Sci.* **95**, 13103–13107

35. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., Hackett, I., Adamson, J., Lincoln, S., Dickson, D., Davies, P., et al. (1998) Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* **393**, 702–705

36. Spillantini, M. G., Goedert, M., Crowther, R. A., Murrell, J. R., Farlow, M. R., and Ghetti, B. (1997) Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 4113–4118

37. Andronesi, O. C., von Bergen, M., Biernat, J., Seidel, K., Griesinger, C., Mandelkow, E., and Baldus, M. (2008) Characterization of Alzheimer’s-like paired helical filaments from the core domain of tau protein using solid-state NMR spectroscopy. *J. Am. Chem. Soc.* **130**, 5922–5928

38. Daebel, V., Chinnathambi, S., Biernat, J., Schwalbe, M., Habenstein, B., Loquet, A., Akoury, E., Tepper, K., Müller, H., Baldus, M., Griesinger, C., Zweckstetter, M., Mandelkow, E., Vijayan, V., and Lange, A. (2012) β-Sheet core of tau paired helical filaments revealed by solid-state NMR. *J. Am. Chem. Soc.* **134**, 13982–13989

39. Margittai, M., and Langen, R. (2004) Template-assisted filament growth by parallel stacking of tau. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 10278–10283

40. Meyer, V., and Margittai, M. (2016) Spin labeling and characterization of Tau fibrils using electron paramagnetic resonance (EPR). *Methods Mol. Biol.* **1345**, 185–199

41. von Bergen, M., Friedhoff, P., Biernat, J., Heberle, J., Mandelkow, E. M., and Mandelkow, E. (2000) Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (VQIIVYK) forming beta structure. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 5129–5134

42. Sawaya, M. R., Sambashivan, S., Nelson, R., Ivanova, M. I., Sievers, S. A., Apostol, M. I., Thompson, M. J., Balbirnie, M., Wiltzus, J. I. W., McFarlane, H. T., Madsen, A. Ø., Riekel, C., and Eisenberg, D. (2007) Atomic structures of amyloid cross-beta spines reveal varied steric zippers. *Nature* **447**, 453–457

43. Grundeke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder, L. I. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proc. Natl. Acad. Sci. U.S.A.* **83**, 4913–4917

44. Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., and Del Tredici, K. (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol.* **112**, 389–404

45. Gandhi, N. S., Landrieu, I., Byrne, C., Kukic, P., Amniai, L., Cantrelle, F.-X., and Mandelkow, E. (2000) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer’s disease-associated neurofibrillary pathology. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 8–18

46. Eichner, T., and Radford, S. E. (2011) A diversity of assembly mechanisms of a generic amyloid model. *Mol. Cell* **43**, 8–18

47. Falcón, B., Zhang, W., Schweighauser, M., Murzin, A. G., Vidal, R., Garriinger, H. J., Ghetti, B., Scheres, S. H. W., and Goedert, M. (2018) Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a common fold. *Acta Neuropathol.* **136**, 699–708

48. Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B. M., and Hamid, M. (2012) scFv antibody: principles and clinical application. *Clin. Dev. Immunol.* **2012**, 980250

49. Huvent, I., Kamah, A., Cantrelle, F.-X., Barois, N., Sliomanni, C., Smet-Nocca, C., Landrieu, I., and Lippens, G. (2014) A functional fragment of Tau forms fibers without the need for an intermolecular cysteine bridge. *Biochem. Biophys. Res. Commun.* **445**, 299–303

50. Niewodk, B., Igaev, M., Sündermann, F., Janning, D., Bakota, L., and Brandt, R. (2016) Presence of a carboxy-terminal pseudorepeat and disease-like pseudohyperphosphorylation critically influence tau’s interaction with microtubules in axon-like processes. *Mol. Biol. Cell* **27**, 3537–3549

51. Wille, H., Drewes, G., Biernat, J., Mandelkow, E. M., and Mandelkow, E. (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. *J. Cell Biol.* **118**, 573–584

52. Bergbom, S., and Mandelkow, E. (2002) Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. *Biochemistry* **41**, 14885–14896

53. Stöhr, J., Wu, H., Nick, M., Wu, Y., Bhave, M., Condello, C., Johnson, N., Rodgers, J., Lemmtn, T., Acharya, S., Becker, J., Robinson, K., Kelly, M. J. S., Gai, F., Stubbs, G., et al. (2017) A 31-residue peptide induces aggregation of tau’s microtubule-binding region in cells. *Nat. Chem.* **9**, 874–881

54. Li, W., and Lee, V. M.-Y. (2006) Characterization of two VQIIXX motifs for tau fibrillation in vitro. *Biochemistry* **45**, 15692–15701

55. Chemerovsky-Glikman, M., Frenkel-Pinter, M., Mdh, R., Abu-Mokh, A., Gázit, E., and Segal, D. (2017) Inhibition of the aggregation and toxicity of the minimal amyloidogenic fragment of Tau by its Pro-substituted analogues. *Chem. Eur. J.* **23**, 9618–9624

56. Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E.-M., Waldmann, H., and Mandelkow, E. (2009) Development of Tau aggregation inhibitors for Alzheimer’s disease. *Angew. Chem. Int. Ed. Engl.* **48**, 1740–1752

57. Cisek, K., Cooper, G. L., Huseby, C. J., and Kuret, J. (2014) Structure and mechanism of action of Tau aggregation inhibitors. *Curr. Alzheimer Res.* **11**, 918–927

58. Landau, M., Sawaya, M. R., Faull, K. F., Laganowsky, A., Jiang, L., Sievers, S. A., Liu, J., Barrio, J. R., and Eisenberg, D. (2011) Towards a pharmacophore for amyloid. *PLoS Biol.* **9**, e1001080

59. Sievers, S. A., Karamanos, J., Chang, H. W., Zhao, A., Jiang, L., Zirafi, O., Stevens, J. T., Münch, J., Baker, D., and Eisenberg, D. (2011) Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. *Nature* **475**, 96–100

60. Wang, C. K., Northfield, S. E., Huang, Y.-H., Ramos, M. C., and Craik, D. J. (2016) Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold. *Eur. J. Med. Chem.* **109**, 342–349

61. Al-Hilaly, Y. K., Pollack, S. J., Vadukul, D. M., Giotossi, F., Rickard, J. E., Simpson, M., Storey, I. M. D., Harrington, C. R., Wischik, C. M., and Serpell, L. C. (2017) Alzheimer’s disease-like paired helical filament assembly from truncated Tau protein is independent of disulfide crosslinking. *J. Mol. Biol.* **429**, 3650–3665

62. Murayama, S., Mori, H., Ibara, Y., and Tomonaga, M. (1990) Immunochemical and ultrastructural studies of Pick’s disease. *Ann. Neurol.* **27**, 394–405

63. Buée, L., and Delacourte, A. (1999) Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. *Brain Pathol.* **9**, 681–693

64. Friedhoff, P., Schneider, A., Mandelkow, E. M., and Mandelkow, E. (1998) Rapid assembly of Alzheimer-like paired helical filaments from microtubu-
cule-associated protein tau monitored by fluorescence in solution. Biochemistry 37, 10223–10230 CrossRef Medline
71. Tacik, P., DeTure, M., Lin, W.-L., Sanchez Contreras, M., Wojtas, A., Hinkle, K. M., Fujioka, S., Baker, M. C., Walton, R. L., Carlonagno, Y., Brown, P. H., Strongosky, A. J., Kouri, N., Murray, M. E., Petruccelli, L., et al. (2015) A novel tau mutation, p.K317N, causes globular glial tauopathy. Acta Neuropathol. 130, 199–214 CrossRef Medline
72. Sibille, N., Sillen, A., Leroy, A., Wieruszeski, J.-M., Mulloy, B., Landrieu, I., and Lippens, G. (2006) Structural impact of heparin binding to full-length Tau as studied by NMR spectroscopy. Biochemistry 45, 12560–12572 CrossRef Medline
73. Carmel, G., Mager, E. M., Binder, L. I., and Kuret, J. (1996) The structural basis of monoclonal antibody Alz50’s selectivity for Alzheimer’s disease pathology. J. Biol. Chem. 271, 32789–32795 CrossRef Medline
74. Jicha, G. A., Bowser, R., Kazam, I. G., and Davies, P. (1997) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128–132 CrossRef Medline
75. Jicha, G. A., Berenfeld, B., and Davies, P. (1999) Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer’s disease. J. Neurosci. Res. 55, 713–723 CrossRef Medline
76. Bibow, S., Mukrasch, M. D., Chinnathambi, S., Biernat, J., Griesinger, C., Mandelkow, E., and Zweckstetter, M. (2011) The dynamic structure of filamentous tau. Angew. Chem. Int. Ed. Engl. 50, 11520–11524 CrossRef Medline
77. Nogales, E., Wolf, S. G., and Downing, K. H. (1998) Structure of the αβ tubulin dimer by electron crystallography. Nature 391, 199–203 CrossRef Medline
78. Makrides, V., Shen, T. E., Bhatia, R., Smith, B. L., Thimm, J., Lal, R., and Feinstein, S. C. (2003) Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. J. Biol. Chem. 278, 33298–33304 CrossRef Medline
79. Duan, A. R., and Goodson, H. V. (2012) Taxol-stabilized microtubules promote the formation of filaments from unmodified full-length Tau in vitro. Mol. Biol. Cell 23, 4796–4806 CrossRef Medline
80. Elbaum-Garfinkle, S., Cobb, G., Compton, J. T., Li, X.-H., and Rhoades, E. (2014) Tau mutants bind tubulin heterodimers with enhanced affinity. Proc. Natl. Acad. Sci. U.S.A. 111, 6311–6316 CrossRef Medline
81. Qiang, L., Sun, X., Austin, T. O., Muralidharan, H., Jean, D. C., Liu, M., Yu, W., and Baas, P. W. (2018) Tau does not stabilize axonal microtubules but rather enables them to have long labile domains. Curr. Biol. 28, 2181–2189.e4 CrossRef Medline
82. Baas, P. W., and Qiang, L. (2019) Tau: it’s not what you think. Trends Cell Biol. 29, 452–461 CrossRef Medline
83. Sato, C., Barthélémy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., Kanaan, N. M., Yarasheski, K. E., Baker-Nigh, A., Benzinger, T. L. S., Miller, T. M., et al. (2018) Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284–1298.e7 CrossRef Medline
84. Prabakaran, S., Lippens, G., Steen, H., and Gunawardena, J. (2012) Post-translational modification: nature’s escape from genetic imprisonment and the basis for dynamic information encoding. Wiley Interdiscip. Rev. Syst. Biol. Med. 4, 565–583 CrossRef Medline
85. Smith, L. M., Kelleher, N. L., and Consortium for Top Down Proteomics (2013) Proteoform: a single term describing protein complexity. Nat. Methods 10, 186–187 CrossRef Medline
86. Despres, C., Byrne, C., Qi, H., Cantrelle, F.-X., Huvent, I., Chambraud, B., Baulieu, E.-E., Jacquot, Y., Landrieu, I., Lippens, G., and Smet-Nocca, C. (2017) Identification of the Tau phosphorylation pattern that drives its aggregation. Proc. Natl. Acad. Sci. U.S.A. 114, 9080–9085 CrossRef Medline
87. Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., Meyers, D., Cole, P. A., Ott, M., and Gan, L. (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966 CrossRef Medline
88. Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., and Lee, V. M. Y. (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252 CrossRef Medline
89. Kamah, A., Huvent, I., Cantrelle, F.-X., Qi, H., Lippens, G., Landrieu, I., and Smet-Nocca, C. (2014) Nuclear magnetic resonance analysis of the acetylation pattern of the neuronal Tau protein. J. Neurosci. Res. 102, 9080–9085 CrossRef Medline
90. Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., and Gong, C.-X. (2004) Tau as studied by NMR spectroscopy. Biochemistry 45, 289, 271, 278, 9080–9085 CrossRef Medline
91. Zhu, Y., Shan, X., Yuzwa, S. A., and Vocadlo, D. J. (2014) The emerging link between the acetylation pattern of the neuronal Tau protein and the basis for dynamic information encoding. Wiley Interdiscip. Rev. Syst. Biol. Med. 4, 565–583 CrossRef Medline
92. Yamashita, T., Fujita, R., and Shiraishi, H. (2013) The structure of tau kinase in complex with 53BP1. Nat. Struct. Mol. Biol. 20, 953–966 CrossRef Medline
93. Lee, V. M. Y. (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252 CrossRef Medline
94. Prabakaran, S., Lippens, G., Steen, H., and Gunawardena, J. (2012) Post-translational modification: nature’s escape from genetic imprisonment and the basis for dynamic information encoding. Wiley Interdiscip. Rev. Syst. Biol. Med. 4, 565–583 CrossRef Medline
95. Smith, L. M., Kelleher, N. L., and Consortium for Top Down Proteomics (2013) Proteoform: a single term describing protein complexity. Nat. Methods 10, 186–187 CrossRef Medline
96. Despres, C., Byrne, C., Qi, H., Cantrelle, F.-X., Huvent, I., Chambraud, B., Baulieu, E.-E., Jacquot, Y., Landrieu, I., Lippens, G., and Smet-Nocca, C. (2017) Identification of the Tau phosphorylation pattern that drives its aggregation. Proc. Natl. Acad. Sci. U.S.A. 114, 9080–9085 CrossRef Medline
97. Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., Meyers, D., Cole, P. A., Ott, M., and Gan, L. (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966 CrossRef Medline
98. Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., and Lee, V. M. Y. (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252 CrossRef Medline
99. Kamah, A., Huvent, I., Cantrelle, F.-X., Qi, H., Lippens, G., Landrieu, I., and Smet-Nocca, C. (2014) Nuclear magnetic resonance analysis of the acetylation pattern of the neuronal Tau protein. J. Biol. Chem. 289, 34472–34481 CrossRef Medline
100. Zhu, Y., Shan, X., Yuzwa, S. A., and Vocadlo, D. J. (2014) The emerging link between O-GlcNAc and Alzheimer disease. J. Biol. Chem. 289, 34472–34481 CrossRef Medline